Penn Medicine

Penn Medicine

Penn Medicine is the unified name for the University of Pennsylvania Health System and the Perelman School of Medicine, both based in Philadelphia. The institution traces its founding to 1765, when the School of Medicine opened as the first medical school in North America. It combines a leading research university with a $5.1B clinical and research operation. The enterprise deploys capital across a broad spectrum: clinical care through six hospitals and a physician network; biomedical research spanning cancer, neuroscience, cardiovascular disease, and genomics; and commercialization of discoveries via licensing and spinouts. Penn Medicine has produced 18 NIH-funded research centers and spun out companies like Spark Therapeutics (gene therapy for inherited blindness, which won FDA approval in 2017) and Inovio Pharmaceuticals, alongside dozens of startups. Geographically, it operates primarily in the Philadelphia region and has a research office in Shanghai, China. Penn Medicine employs over 48,000 people and generates annual revenue exceeding $10B. It maintains a $10B+ endowment managed separately by the University of Pennsylvania's investment office. The institution's clinical arm, UPHS, reported operating income of $1.1B in fiscal 2023. Penn Medicine operates philanthropic and venture vehicles such as the Penn Medicine Development Office and Penn Center for Innovation, which acts as a tech transfer and startup accelerator. What structurally sets Penn Medicine apart is its identity as a vertically integrated academic medical center — it is not a family office, endowment, or venture firm, but a debt-funded $10B revenue enterprise that simultaneously performs the world's most cited clinical research, trains medical students, and operates a massive health system. Its investment strategy is subordinate to patient care and discovery mandates, making it distinct from pure allocator models.